PatSnap Synapse
2023-05-1240 Pages

Global Drug R&D Express (Apr. 2023)

report cover
Abstract
Based on the latest data from SYNAPSE, we has released the "Global Drug R&D Express (Apr. 2023)". The report includes a total of 53 drugs consisting of: ◉ 8 drugs first approved globally: 2 Prophylactic vaccine, 2 Small molecule drug (SMD), 1 Monoclonal antibody(mAb), 1 Hematopoietic stem cell, 1 Oligonucleotide antisense, 1 Live biotherapeutic products. ◉ 45 drugs under Expedited Review pathways worldwide: 16 Orphan Drug designation, 12 Fast Track designation, 6 Breakthrough Therapy designation, 4 Priority review, 2 Rare Pediatric Disease designation, 2 Innovative Licensing and Access Pathway (ILAP), 1 Accelerated Approval, 1 Emergency Use Authorization, 1 PRIME (EU). The report also highlights: ◼ 5 first approved drugs: Vilobelimab、R21/Matrix-M、Omidubicel、Reassortant Rotavirus Vaccine、AKEEGA. ◼ 7 Expedited Review Pathway drugs: Remternetug、Sibeprenlimab、HH-003、FCN-159、SAB-176、Resmetirom、CB-011. providing a comprehensive analysis of each, including their snapshot, R&D status, active patents, mechanisms of action, clinical trial information, and competitive landscape.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free